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In summary, following a single oral dose of DCA to 
laboratory rats, peak hepatic tissue DCA concentration 
occurred at 3 hr. When given chronically for 7 days, DCA 
caused activation of the pyruvate dehydrogenase complex 
which returned to basal activity 24 hr following the final 
dose. Hepatic tissue DCA concentrations were maximally 
increased at 3 hr following the final dose, and the drug was 
eliminated slowly over 72 hr with a half-life of 9.74 hr. 
Liver and muscle showed similar DCA tissue concentra- 
tions following chronic administration. 
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Inhibition of carrageenin-induced rat footpad edema by systemic treatment with 
prostaglandins of the E series 
(Received 4 December 1981; accepted 25 March 1982) 
One of the most widely used models for evaluation of 
anti-inflammatory agents is carrageenin-induced edema in 
the rat footpad [l]. This reaction consists of three distinct 
phases of mediator-induced vascular permeability changes. 
The initial phase, during the first 30min after injection, 
results from the release of histamine and serotonin from 
host cells and is inhibited by anti-histamines [2]. The second 
phase, between 1 and 2.5 hr after injection, is attributed 
to the action of bradykinin since pretreatment of rats with 
cellulose sulfate (which lowers plasma kininogen levels) 
reduces edema. The third phase of persistent edema is 
complement-dependent and has been attributed to the local 
production of prostaglandins, especially of the E series, by 
inflammatory cells [3-61. This phase of edema formation 
is inhibited by indomethacin and aspirin, and is potentiated 
by the local injection of vasodilatory prostaglandins such 
as PGE2 [7,8]. However, additional studies suggest that 
stimulation of prostaglandin production may have inhibi- 
tory effects on carrageenin-induced edema [9]. Recent stud- 
ies in our laboratory have shown that systemic treatment 
of rats with prostaglandins, especially of the E series, will 
inhibit vascular permeability changes induced by the vaso- 
active mediators histamine, serotonin, bradykinin, com- 
pound 48180 and the anaphylatoxin C3a [lo]. In this report, 
we examine the effects of systemic prostaglandin treatment 
of rats on carrsgeenin-induced vascular permeability 
changes. 
Carrageenin edema was induced by the intradermal 
injection of 0.1 ml of 1% carrageenin (viscarin 402) (Marine 
Colloids, Springfield, NJ), dissolved in phosphate-buffered 
saline (PBS), pH 7.4, into the hind paw of Sprague-Dawley 
rats weighing 200-250 g (Charles River Laboratories, 
Portage, MI). Separate groups of three to five rats were 
pretreated (subcutaneously) with prostaglandins 1 hr prior 
to carrageenin injection. Footpad thickness was measured 
at various times after carrageenin injection with a Mitutoyo 
micrometer. Prostaglandins (PG) were provided by Dr. 
John Pike (Upjohn Co., Kalamazoo MI). Student’s t-test 
(two tailed) was used to compare PG-treated animals with 
non-treated control animals. 
The effect of systemic treatment of rats with 15-S-15- 
methvl PGE, (1.5-M-PGE,) on carraeeenin-induced foot- 
pad edema is shown in Fig-.’ 1. When i5-M-PGE, at a dose 
of 1 mg/kg was administered S.C. 1 hr prior to carrageenin 
injection, there was significant inhibition of rat footpad 
edema formation as compared to control values. Both the 
acute phase (47.1% inhibition at 1 hr, P < 0.001) of edema 
formation mediated bv histamine, serotonin, and bradv- 
kinin and the later -phase (61.0% inhibition at 6 hr, 
P < 0.001) which is inhibited bv indomethacin and asoirin 
were reduced significantly. Inhibition of footpad edema 
formation by 15-M-PGE, was dose dependent with sig- 
nificant inhibition (40.7% at 1 hr, P < 0.001 and 37.7% at 
6 hr, P < 0.001) occurring at a dose of 0.2 ogikg and only 
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Fig. 1. Effect of systemic treatment of rats with 15-S-15- 
methyl PGEi on carrageenin-induced footpad edema. 
Groups of four rats received 15-M-PGE, at various doses 
S.C. 1 hr prior to injection of carrageenin into the rat foot- 
pad. Footpad thickness was measured at 1 hr intervals after 
carrageenin injection. The mean value for each group of 
four animals is shown f the standard error of the mean. 
Key: (0) control; (A) 15-M-PGEi, O.O4mg/kg; (0) 15- 
M-PGE,, 0.2 mg/kg; and (0) 15-M-PGEi, 1 mg/kg. 
slight inhibition of edema formation at a dose of 
0.04 mg/kg. 
The specificity of the inhibition of carrageenin-induced 
edema is shown in Fig. 2. When prostaglandins were 
administered 1 hr prior to carrageenin treatment at con- 
centrations of 1 mg/kg, 15-M-PGEi showed the greatest 
inhibition of edema formation (see above) while PGEi 
(49.5% inhibition at 6 hr, P < 0.001) and PGE2 (34.4% 
inhibition at 6 hr, P < 0.001) at the same concentration 
showed significant inhibition of only the later phase of 
edema formation. Treatment of rats with PGFr,, a potent 
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Fig. 2. Effects of systemic treatment of rats with 15-S-15- 
methyl PGE,, PGEi, PGEr and PGFrn on carrageenin- 
induced footpad edema. Groups of four rats received 
individual prostaglandins (1 mg/kg) S.C. 1 hr prior to injec- 
tion of carrageenin into the rate footpad. Footpad thickness 
was measured at l-hr intervals after carrageenin injection. 
The mean value for each group of four animals is shown 
C the standard error of the mean. Key: (0) control; (0) 
Fig. 3. Time dependence of the inhibitory effect of 15- 
M-PGEi on carrageenin-induced footpad edema. 15-M- 
PGEi (1 mgikg, s.c.) was administered 1, 24 and 48 hr to 
groups of four animals prior to injection of carrageenin 
into the rat footpad. Footped thickness was measured at 
l-hr intervals after carrageenin injection. The mean value 
for each group of four animals is shown ? the standard 
error of the mean. Key: (0) control; (0) 15-M-PGEi 
administered 1 hr prior to carrageenin injection; (0) 15- 
M-PGEi administered 24 hr prior to carrageenin injection; 
and (A) 15-M-PGEl administered 48 hr prior to carra- 
PGF*,; (A) PGEr; (0) PGEi; and (0) 15-M-PGE1. geenin injection. 
vasoconstrictor [ll], had no effect on carrageenin-induced 
edema formation. The difference in activity between 15- 
M-PGEi and PGEi is most likely a result of the increased 
stability and resistance to hydrolysis by 15-hydroxy- 
prostaglandin dehydrogenase of the 15-methyl analog [12]. 
The time dependence of the inhibitory effect of 15-M- 
PGEi on edema formation is shown in Fig. 3. Significant 
inhibition of both the early and late phases of 
carrageenin-induced edema was observed when animals 
received carrageenin at 1 (see above) and 24 (39.0% inhi- 
bition at 1 hr, P < 0.001, and 41.3% inhibition at 6 hr, 
P < 0.001) hr after treatment with 15-M-PGE1 (1 mgikg, 
s.c.). However, when animals were challenged at 48 hr 
after 15-M-PGEi treatment, there was only minimal inhi- 
bition (12.6% inhibition at 6 hr) of edema formation. 
The data presented here show that systemic treatment 
of animals with prostaglandins of the E series will inhibit 
carrageenin-induced edema in the rat footpad in both a 
dose- and time-dependent manner. In addition, the inhibi- 
tory effects of PGs on carrageenin-induced edema 
formation show at least partial specificity for PGs of the 
E series since PGFr, had no effect. 
Inhibition of the earlier phases of carrageenin-induced 
permeability changes by PGEi and PGEr is consistent with 
initial studies in which systemic treatment of rats with PGE, 
and PGE2 inhibited edema formation induced by histamine, 
bradykinin and serotonin [lo] as well as other acute and 
chronic inflammatory reactions [4, 13-151. The inhibition 
of edema formation at >6 hr after carrageenin treatment 
by PGEi and PGEr suggests that there are marked differ- 
ences between the local and systemic effects of prosta- 
glandins on acute inflammatory reactions. Several authors 
have shown that the local injection of prostaglandins of the 
E series will potentiate leakage of plasma proteins due to 
histamine, bradykinin, and carrageenin secondary to 
PGE-induced vasodilation [4,7, 16-181. However, the dose 
of locally administered PGE is frequently in the range of 
1 pg, and it is unlikely that S.C. administration of 15-M- 
PGEl at 0.2 mgikg or PGEr at 1.0 mgikg resulted in com- 
parable local concentrations 1 hr later. Therefore, the con- 
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trasting effects between systemic and local administration 
of PGEs may reflect a dose effect of PGEs on the vascular 
wall and edema formation. 
Additional studies have demonstrated increased levels 
of PGEr in exudates at 3-6 hr after carrageenin adminis- 
tration [8, 181. Although this later phase of edema 
formation is inhibited by aspirin and indomethacin [2,3], 
this is only indirect evidence implicating PGE2 as a pro- 
inflammatory agent. It is possible that the increased level 
of PGEr previously reported in acute carrageenin inflam- 
matory sites is not the causative agent of the persistent 
edema. Several authors have shown that the so-called pros- 
taglandin phase of vascular permeability change is depen- 
dent on the generation of superoxide anion (Oj) and is 
inhibited by superoxide dismutase and specific scavengers 
of oxygen-derived free radicals [ 191. Since oxygen-derived 
free radicals and their metabolites have been shown to 
cause tissue injury, it is possible that their production is 
responsible for the delayed carrageenin-induced edema 
formation [20-221. 
Recent studies have also shown that the effects of 
indomethacin and aspirin are not as specific as originally 
described. Since both compounds have been shown to 
inhibit the production of lipoxygenase products of arach- 
idonic acid metabolism [23,24], and indomethacin to inhibit 
oxygen free radical production [25] and release of lysosomal 
enzymes from inflammatory cells [25,26], it is possible that 
the delayed permeability changes induced by carrageenin 
are not secondary to PGEr, as previously described, but 
are the result of the local production of lipoxygenase prod- 
ucts and/or oxygen-derived free radicals. The increased 
PGE levels demonstrated in early acute inflammatory 
reactions may, in fact, represent a modulating system that 
controls and limits the extent of the inflammatory response. 
The data demonstrate that systemic treatment of rats 
with prostaglandins of the E series inhibited carrageenin- 
induced edema formation. In addition, not only were the 
acute changes in vascular permeability inhibited but the 
delayed persistent permeability change previously attri- 
buted to the local generation of prostaglandins was also 
suppressed. The data support the previously described 
anti-inflammatory effects of systemic treatment with prosta- 
glandins of the E series in uivo and suggest that they may 
be of future use in therapeutic modulation of edema 
formation and inflammatory reactions. 
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Methylation of norepinephrine and cu-methylnorepinephrine in brain 
(Received 11 January 1982; accepted 13 April 1982) 
Because of the anatomic location of epinephrine-forming drugs act by influencing epinephrine-forming neurons or 
neurons in rat brain, attention has been focused recently receptors for these neurons in brain has also been suggested 
on their possible role in the central regulation of blood [2-51. 
pressure [l-3]. The possibility that some antihypertensive Recently, Beart et al. [6,7] have reported that cu-meth- 
